Skip to content

Study · Animal study (in vivo) · rat · 1994

17 results

Effects of insulin-like growth factor-I peptides in rats with acute renal failure.

Martin AA, Gillespie CM, Moore L, Ballard FJ, Read LC

The Journal of endocrinology1 Jan 1994Cited by 4 (Europe PMC)

PMID8138750 (opens in a new tab)DOI10.1677/joe.0.1400023 (opens in a new tab)PepBankPUB-08138750
Publisher pagePubMedAsk about this study
Jump to 17 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study17

17 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In rats with acute renal ischaemia, body weight gain was significantly improved in the LR3IGF-I group.

    In plain wordsIn rats with acute kidney injury, the LR3 IGF-I analogue improved weight gain.

    Peptide
    IGF-1 LR3
    Outcome
    IncreaseBody weight gain
    Study

    ratn: not reported in source

    male Sprague-Dawley rats with acute renal failure after 45 min renal artery clamping
    Comparator
    vehicle
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    1.5 mg/kg per day · subcutaneous osmotic pump · 7 daysAs given in this study (rat).

    Source sentences

    Summary
    Following the episode of renal ischaemia, body weight gain and nitrogen retention were significantly improved in all three peptide-treated groups
    1 context sentence
    Summary · context
    Acute renal failure was produced in male Sprague-Dawley rats by clamping both renal arteries for 45 min.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In rats with acute renal ischaemia, nitrogen retention was significantly improved in the LR3IGF-I group.

    In plain wordsIn rats with acute kidney injury, the LR3 IGF-I analogue improved nitrogen retention.

    Peptide
    IGF-1 LR3
    Outcome
    IncreaseNitrogen retention
    Study

    ratn: not reported in source

    male Sprague-Dawley rats with acute renal failure after 45 min renal artery clamping
    Comparator
    vehicle
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    1.5 mg/kg per day · subcutaneous osmotic pump · 7 daysAs given in this study (rat).

    Source sentences

    Summary
    Following the episode of renal ischaemia, body weight gain and nitrogen retention were significantly improved in all three peptide-treated groups
    1 context sentence
    Summary · context
    Acute renal failure was produced in male Sprague-Dawley rats by clamping both renal arteries for 45 min.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In rats with acute renal ischaemia, the variants including LR3IGF-I had no increased potency over the growth effects of IGF-I.

    In plain wordsIn rats with acute kidney injury, the LR3 IGF-I analogue was not more potent than IGF-I for growth effects.

    Peptide
    IGF-1 LR3
    Outcome
    No significant changeGrowth potency versus IGF-I
    Study

    ratn: not reported in source

    male Sprague-Dawley rats with acute renal failure after 45 min renal artery clamping
    Comparator
    IGF-I
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    1.5 mg/kg per day · subcutaneous osmotic pump · 7 daysAs given in this study (rat).

    Source sentences

    Summary
    However, there was no evidence of the variants having any increased potency over the growth effects of IGF-I itself.
    1 context sentence
    Summary · context
    Acute renal failure was produced in male Sprague-Dawley rats by clamping both renal arteries for 45 min.
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    In rats with acute renal ischaemia, GFR was reduced in all groups, with no significant effect of the IGF peptides.

    In plain wordsIn rats with acute kidney injury, kidney filtration fell in all groups, and the IGF peptides did not change this.

    Peptide
    IGF-1 LR3
    Outcome
    No significant changeGlomerular filtration rate
    Study

    ratn: not reported in source

    male Sprague-Dawley rats with acute renal failure after 45 min renal artery clamping
    Comparator
    vehicle
    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    1.5 mg/kg per day · subcutaneous osmotic pump · 7 daysAs given in this study (rat).

    Source sentences

    Summary
    GFR was significantly reduced, urine output was increased and urinary concentrating ability was reduced in all groups compared with normal rats, with no significant effect of the IGF peptides being apparent.
    1 context sentence
    Summary · context
    Acute renal failure was produced in male Sprague-Dawley rats by clamping both renal arteries for 45 min.
  5. 05AnimalAnimal study (in vivo)Efficacy outcome

    In rats with acute renal ischaemia, urine output was increased in all groups, with no significant effect of the IGF peptides.

    In plain wordsIn rats with acute kidney injury, urine output rose in all groups, and the IGF peptides did not change this.

    Peptide
    IGF-1 LR3
    Outcome
    No significant changeUrine output
    Study

    ratn: not reported in source

    male Sprague-Dawley rats with acute renal failure after 45 min renal artery clamping
    Comparator
    vehicle
    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    1.5 mg/kg per day · subcutaneous osmotic pump · 7 daysAs given in this study (rat).

    Source sentences

    Summary
    GFR was significantly reduced, urine output was increased and urinary concentrating ability was reduced in all groups compared with normal rats, with no significant effect of the IGF peptides being apparent.
    1 context sentence
    Summary · context
    Acute renal failure was produced in male Sprague-Dawley rats by clamping both renal arteries for 45 min.
  6. 06AnimalAnimal study (in vivo)Efficacy outcome

    In rats with acute renal ischaemia, urinary concentrating ability was reduced in all groups, with no significant effect of the IGF peptides.

    In plain wordsIn rats with acute kidney injury, urine concentrating ability fell in all groups, and the IGF peptides did not change this.

    Peptide
    IGF-1 LR3
    Outcome
    No significant changeUrinary concentrating ability
    Study

    ratn: not reported in source

    male Sprague-Dawley rats with acute renal failure after 45 min renal artery clamping
    Comparator
    vehicle
    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    1.5 mg/kg per day · subcutaneous osmotic pump · 7 daysAs given in this study (rat).

    Source sentences

    Summary
    GFR was significantly reduced, urine output was increased and urinary concentrating ability was reduced in all groups compared with normal rats, with no significant effect of the IGF peptides being apparent.
    1 context sentence
    Summary · context
    Acute renal failure was produced in male Sprague-Dawley rats by clamping both renal arteries for 45 min.
  7. 07AnimalAnimal study (in vivo)Safety outcome

    In rats with renal ischaemia, LR3IGF-I treatment resulted in a significantly greater fall in GFR than in controls.

    In plain wordsIn rats with acute kidney injury, the LR3 IGF-I analogue made kidney filtration fall more than in untreated rats.

    Peptide
    IGF-1 LR3
    Outcome
    DecreaseFall in GFR over 3 days after ischaemia
    Study

    ratn: not reported in source

    male Sprague-Dawley rats with acute renal failure after 45 min renal artery clamping
    Comparator
    vehicle
    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    1.5 mg/kg per day · subcutaneous osmotic pump · 3 daysAs given in this study (rat).

    Source sentences

    Summary
    LR3IGF-I treatment following renal ischaemia resulted in a significantly greater fall in GFR than in controls, urinary osmolality was also significantly reduced, and fractional excretion of sodium was increased.
    2 context sentences
    Summary · context
    A closer examination of the acute effects of LR3IGF-I on renal function was undertaken by measuring GFR for 3 days before and 3 days after renal ischaemia in two groups of rats, treated for the latter 3 days with either vehicle (controls) or LR3IGF-I (1.5 mg/kg per day).
    Summary · context
    Acute renal failure was produced in male Sprague-Dawley rats by clamping both renal arteries for 45 min.
  8. 08AnimalAnimal study (in vivo)Safety outcome

    In rats with renal ischaemia, LR3IGF-I treatment significantly reduced urinary osmolality compared with controls.

    In plain wordsIn rats with acute kidney injury, the LR3 IGF-I analogue lowered urine concentration compared with untreated rats.

    Peptide
    IGF-1 LR3
    Outcome
    DecreaseUrinary osmolality
    Study

    ratn: not reported in source

    male Sprague-Dawley rats with acute renal failure after 45 min renal artery clamping
    Comparator
    vehicle
    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    1.5 mg/kg per day · subcutaneous osmotic pump · 3 daysAs given in this study (rat).

    Source sentences

    Summary
    LR3IGF-I treatment following renal ischaemia resulted in a significantly greater fall in GFR than in controls, urinary osmolality was also significantly reduced, and fractional excretion of sodium was increased.
    2 context sentences
    Summary · context
    A closer examination of the acute effects of LR3IGF-I on renal function was undertaken by measuring GFR for 3 days before and 3 days after renal ischaemia in two groups of rats, treated for the latter 3 days with either vehicle (controls) or LR3IGF-I (1.5 mg/kg per day).
    Summary · context
    Acute renal failure was produced in male Sprague-Dawley rats by clamping both renal arteries for 45 min.
  9. 09AnimalAnimal study (in vivo)Safety outcome

    In rats with renal ischaemia, LR3IGF-I treatment increased fractional excretion of sodium compared with controls.

    In plain wordsIn rats with acute kidney injury, the LR3 IGF-I analogue increased sodium loss in urine compared with untreated rats.

    Peptide
    IGF-1 LR3
    Outcome
    IncreaseFractional excretion of sodium
    Study

    ratn: not reported in source

    male Sprague-Dawley rats with acute renal failure after 45 min renal artery clamping
    Comparator
    vehicle
    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    1.5 mg/kg per day · subcutaneous osmotic pump · 3 daysAs given in this study (rat).

    Source sentences

    Summary
    LR3IGF-I treatment following renal ischaemia resulted in a significantly greater fall in GFR than in controls, urinary osmolality was also significantly reduced, and fractional excretion of sodium was increased.
    2 context sentences
    Summary · context
    A closer examination of the acute effects of LR3IGF-I on renal function was undertaken by measuring GFR for 3 days before and 3 days after renal ischaemia in two groups of rats, treated for the latter 3 days with either vehicle (controls) or LR3IGF-I (1.5 mg/kg per day).
    Summary · context
    Acute renal failure was produced in male Sprague-Dawley rats by clamping both renal arteries for 45 min.
  10. 10AnimalAnimal study (in vivo)Safety outcome

    In rats with renal ischaemia, kidneys treated with LR3IGF-I showed histological evidence of a greater degree of tubular epithelial calcification.

    In plain wordsIn rats with acute kidney injury, the LR3 IGF-I analogue was linked to more calcium deposits in kidney tubules.

    Peptide
    IGF-1 LR3
    Outcome
    IncreaseTubular epithelial calcification
    Study

    ratn: not reported in source

    male Sprague-Dawley rats with acute renal failure after 45 min renal artery clamping
    Comparator
    vehicle
    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    1.5 mg/kg per day · subcutaneous osmotic pump · 3 daysAs given in this study (rat).

    Source sentences

    Summary
    In addition, there was histological evidence of a greater degree of tubular epithelial calcification in the kidneys of the rats treated with LR3IGF-I.
    2 context sentences
    Summary · context
    A closer examination of the acute effects of LR3IGF-I on renal function was undertaken by measuring GFR for 3 days before and 3 days after renal ischaemia in two groups of rats, treated for the latter 3 days with either vehicle (controls) or LR3IGF-I (1.5 mg/kg per day).
    Summary · context
    Acute renal failure was produced in male Sprague-Dawley rats by clamping both renal arteries for 45 min.
  11. 11AnimalAnimal study (in vivo)Efficacy outcome

    In rats after renal ischaemia, des(1‑3)IGF-I significantly improved body weight gain versus vehicle.

    In plain wordsIn rats after kidney ischaemia, des(1‑3)IGF-I improved weight gain compared with vehicle.

    Peptide
    IGF-1 DES (des(1-3)IGF-I)
    Outcome
    IncreaseBody weight gain
    Study

    ratn: not reported in source

    Male Sprague-Dawley rats with renal ischaemia
    Comparator
    Vehicle
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    2.0 mg/kg per day · subcutaneous osmotic pump · 7 daysAs given in this study (rat).

    Source sentences

    Summary
    Following the episode of renal ischaemia, body weight gain and nitrogen retention were significantly improved in all three peptide-treated groups, and serum urea concentrations were reduced in the groups treated with IGF-I and des(1-3)IGF-I.
    2 context sentences
    Summary · context
    Acute renal failure was produced in male Sprague-Dawley rats by clamping both renal arteries for 45 min.
    Summary · context
    Treatment was commenced at the time of renal artery occlusion with vehicle (0.1 mol acetic acid/l; control group), IGF-I (2.0 mg/kg per day), des(1-3)IGF-I (2.0 mg/kg per day) or LR3IGF-I (1.5 mg/kg per day) by s.c. osmotic pump, and continued for 7 days, with rats being held in metabolism cages.
  12. 12AnimalAnimal study (in vivo)Efficacy outcome

    In rats after renal ischaemia, des(1‑3)IGF-I significantly improved nitrogen retention versus vehicle.

    In plain wordsIn rats after kidney ischaemia, des(1‑3)IGF-I improved nitrogen retention compared with vehicle.

    Peptide
    IGF-1 DES (des(1-3)IGF-I)
    Outcome
    IncreaseNitrogen retention
    Study

    ratn: not reported in source

    Male Sprague-Dawley rats with renal ischaemia
    Comparator
    Vehicle
    Outcome group
    Protein and amino acid metabolism · Metabolic and weight
    Studied dose
    2.0 mg/kg per day · subcutaneous osmotic pump · 7 daysAs given in this study (rat).

    Source sentences

    Summary
    Following the episode of renal ischaemia, body weight gain and nitrogen retention were significantly improved in all three peptide-treated groups, and serum urea concentrations were reduced in the groups treated with IGF-I and des(1-3)IGF-I.
    2 context sentences
    Summary · context
    Acute renal failure was produced in male Sprague-Dawley rats by clamping both renal arteries for 45 min.
    Summary · context
    Treatment was commenced at the time of renal artery occlusion with vehicle (0.1 mol acetic acid/l; control group), IGF-I (2.0 mg/kg per day), des(1-3)IGF-I (2.0 mg/kg per day) or LR3IGF-I (1.5 mg/kg per day) by s.c. osmotic pump, and continued for 7 days, with rats being held in metabolism cages.
  13. 13AnimalAnimal study (in vivo)Efficacy outcome

    In rats after renal ischaemia, des(1‑3)IGF-I reduced serum urea versus vehicle.

    In plain wordsIn rats after kidney ischaemia, des(1‑3)IGF-I reduced blood urea compared with vehicle.

    Peptide
    IGF-1 DES (des(1-3)IGF-I)
    Outcome
    DecreaseSerum urea
    Study

    ratn: not reported in source

    Male Sprague-Dawley rats with renal ischaemia
    Comparator
    Vehicle
    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    2.0 mg/kg per day · subcutaneous osmotic pump · 7 daysAs given in this study (rat).

    Source sentences

    Summary
    Following the episode of renal ischaemia, body weight gain and nitrogen retention were significantly improved in all three peptide-treated groups, and serum urea concentrations were reduced in the groups treated with IGF-I and des(1-3)IGF-I.
    2 context sentences
    Summary · context
    Acute renal failure was produced in male Sprague-Dawley rats by clamping both renal arteries for 45 min.
    Summary · context
    Treatment was commenced at the time of renal artery occlusion with vehicle (0.1 mol acetic acid/l; control group), IGF-I (2.0 mg/kg per day), des(1-3)IGF-I (2.0 mg/kg per day) or LR3IGF-I (1.5 mg/kg per day) by s.c. osmotic pump, and continued for 7 days, with rats being held in metabolism cages.
  14. 14AnimalAnimal study (in vivo)Efficacy outcome

    In rats after renal ischaemia, des(1‑3)IGF-I showed no evidence of greater growth potency than IGF-I.

    In plain wordsIn rats after kidney ischaemia, des(1‑3)IGF-I showed no greater growth potency than IGF-I.

    Peptide
    IGF-1 DES (des(1-3)IGF-I)
    Outcome
    No significant changeGrowth potency versus IGF-I
    Study

    ratn: not reported in source

    Male Sprague-Dawley rats with renal ischaemia
    Comparator
    IGF-I
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    2.0 mg/kg per day · subcutaneous osmotic pump · 7 daysAs given in this study (rat).

    Source sentences

    Summary
    However, there was no evidence of the variants having any increased potency over the growth effects of IGF-I itself.
    3 context sentences
    Summary · context
    Since the des(1-3)IGF-I and LR3IGF-I variant forms of IGF-I have been shown to be more potent than IGF-I, their effects were also examined.
    Summary · context
    Acute renal failure was produced in male Sprague-Dawley rats by clamping both renal arteries for 45 min.
    Summary · context
    Treatment was commenced at the time of renal artery occlusion with vehicle (0.1 mol acetic acid/l; control group), IGF-I (2.0 mg/kg per day), des(1-3)IGF-I (2.0 mg/kg per day) or LR3IGF-I (1.5 mg/kg per day) by s.c. osmotic pump, and continued for 7 days, with rats being held in metabolism cages.
  15. 15AnimalAnimal study (in vivo)Efficacy outcome

    In rats after renal ischaemia, des(1‑3)IGF-I had no significant effect on glomerular filtration rate versus vehicle.

    In plain wordsIn rats after kidney ischaemia, des(1‑3)IGF-I did not significantly change kidney filtration compared with vehicle.

    Peptide
    IGF-1 DES (des(1-3)IGF-I)
    Outcome
    No significant changeGlomerular filtration rate
    Study

    ratn: not reported in source

    Male Sprague-Dawley rats with renal ischaemia
    Comparator
    Vehicle
    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    2.0 mg/kg per day · subcutaneous osmotic pump · 7 daysAs given in this study (rat).

    Source sentences

    Summary
    GFR was significantly reduced, urine output was increased and urinary concentrating ability was reduced in all groups compared with normal rats, with no significant effect of the IGF peptides being apparent.
    2 context sentences
    Summary · context
    Acute renal failure was produced in male Sprague-Dawley rats by clamping both renal arteries for 45 min.
    Summary · context
    Treatment was commenced at the time of renal artery occlusion with vehicle (0.1 mol acetic acid/l; control group), IGF-I (2.0 mg/kg per day), des(1-3)IGF-I (2.0 mg/kg per day) or LR3IGF-I (1.5 mg/kg per day) by s.c. osmotic pump, and continued for 7 days, with rats being held in metabolism cages.
  16. 16AnimalAnimal study (in vivo)Efficacy outcome

    In rats after renal ischaemia, des(1‑3)IGF-I had no significant effect on urine output versus vehicle.

    In plain wordsIn rats after kidney ischaemia, des(1‑3)IGF-I did not significantly change urine output compared with vehicle.

    Peptide
    IGF-1 DES (des(1-3)IGF-I)
    Outcome
    No significant changeUrine output
    Study

    ratn: not reported in source

    Male Sprague-Dawley rats with renal ischaemia
    Comparator
    Vehicle
    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    2.0 mg/kg per day · subcutaneous osmotic pump · 7 daysAs given in this study (rat).

    Source sentences

    Summary
    GFR was significantly reduced, urine output was increased and urinary concentrating ability was reduced in all groups compared with normal rats, with no significant effect of the IGF peptides being apparent.
    2 context sentences
    Summary · context
    Acute renal failure was produced in male Sprague-Dawley rats by clamping both renal arteries for 45 min.
    Summary · context
    Treatment was commenced at the time of renal artery occlusion with vehicle (0.1 mol acetic acid/l; control group), IGF-I (2.0 mg/kg per day), des(1-3)IGF-I (2.0 mg/kg per day) or LR3IGF-I (1.5 mg/kg per day) by s.c. osmotic pump, and continued for 7 days, with rats being held in metabolism cages.
  17. 17AnimalAnimal study (in vivo)Efficacy outcome

    In rats after renal ischaemia, des(1‑3)IGF-I had no significant effect on urinary concentrating ability versus vehicle.

    In plain wordsIn rats after kidney ischaemia, des(1‑3)IGF-I did not significantly change urine concentrating ability compared with vehicle.

    Peptide
    IGF-1 DES (des(1-3)IGF-I)
    Outcome
    No significant changeUrinary concentrating ability
    Study

    ratn: not reported in source

    Male Sprague-Dawley rats with renal ischaemia
    Comparator
    Vehicle
    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    2.0 mg/kg per day · subcutaneous osmotic pump · 7 daysAs given in this study (rat).

    Source sentences

    Summary
    GFR was significantly reduced, urine output was increased and urinary concentrating ability was reduced in all groups compared with normal rats, with no significant effect of the IGF peptides being apparent.
    2 context sentences
    Summary · context
    Acute renal failure was produced in male Sprague-Dawley rats by clamping both renal arteries for 45 min.
    Summary · context
    Treatment was commenced at the time of renal artery occlusion with vehicle (0.1 mol acetic acid/l; control group), IGF-I (2.0 mg/kg per day), des(1-3)IGF-I (2.0 mg/kg per day) or LR3IGF-I (1.5 mg/kg per day) by s.c. osmotic pump, and continued for 7 days, with rats being held in metabolism cages.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Versions 3 to 4Current

    21 Oct 2026, 13:52 UTC

    The same notice was added 2 times, first on 21 Oct 2026, 12:50 UTC. The status did not change between them.

    Study data updated · source update from Europe PMC

  2. Version 2

    13 Oct 2026, 21:44 UTC

    Study results updated

  3. Version 1

    13 Oct 2026, 16:31 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.